Measures in the first year of therapy predict the response to interferon β in MS
Jordi Río(Universitat Autònoma de Barcelona), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Mar Tintoré(Vall d'Hebron Hospital Universitari), X Aymerich(Vall d'Hebron Hospital Universitari), Àlex Rovira(Centre National de la Recherche Scientifique), Alejandro Horga(Hospital Clínico San Carlos), Manuel Comabella(Universitat Autònoma de Barcelona), Carlos Nos(Universitat Autònoma de Barcelona), Joaquín Castilló(Universitat Autònoma de Barcelona), Jaume Sastre‐Garriga(Universitat Autònoma de Barcelona)
Cited by 242
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k